PHR1817

Furosemide Related Compound A

Pharmaceutical Secondary Standard; Certified Reference Material

• 別名: 2-Chloro-4-furfurylamino-5-sulfamoylbenzoic acid, 2-CHLORO-4-N-FURFURYLAMINO -5-SULFAMOYLBENZOIC ACID
• 実験式（ヒル表記法）: C₁₂H₁₁ClN₂O₅S
• CAS番号: 4818-59-1
• 分子量: 330.74
• Beilstein: 1297887
• MDL番号: MFCD18379506
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: certified reference material; pharmaceutical secondary standard
• 品質水準: 300
• 認証: traceable to Ph. Eur. F0702000; traceable to USP 1287020
• CofA: current certificate can be downloaded
• 包装: pkg of 100 mg
• mp: 197 °C (dec.) (lit.)
• アプリケーション: pharmaceutical
• フォーマット: neat
• 保管温度: 2-30°C
• SMILES記法: OC(C1=C(Cl)C=C(NCC2=CC=CO2)C(S(N)(=O)=O)=C1)=O
• InChI: 1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)11(21(14,18)19)4-8(9)12(16)17/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
• InChI Key: UXOOVYKVEXGCSH-UHFFFAOYSA-N

詳細

詳細

Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards

アプリケーション

• Furosemide Impurity A for Quality Control: Furosemide Related Compound A serves as a crucial standard in pharmaceutical quality control, ensuring the purity and safety of furosemide as an active pharmaceutical ingredient. This impurity standard is essential for regulatory compliance and batch-to-batch consistency in drug manufacturing (Abasilim et al., 2023).


• Research on Drug Resistance: Furosemide Related Compound A is utilized in genomic research to identify potential drug resistance mechanisms. This research aids in understanding how bacterial pathogens develop resistance to drugs like clarithromycin and rifampicin, which is crucial for developing new therapeutic strategies (Mofidifar et al., 2024).


• Nanotechnology in Drug Delivery: High-purity Furosemide Related Compound A is used in the preparation and characterization of novel drug delivery systems, such as nanoparticles designed to enhance the bioavailability and efficacy of pharmaceutical compounds. This research highlights its application in improving drug formulations and targeting specific disease sites (Zeng et al., 2024).


• Impact on Bone Health: Research involving Furosemide Related Compound A explores its effects on bone health, particularly in how it influences vitamin D metabolism and bone density. This is vital for developing treatments that mitigate bone density loss associated with long-term use of diuretics like furosemide (Melanie KF et al., 2024).


• Nutritional Studies in Cancer Therapy: Furosemide Related Compound A is also examined for its role in nutritional interventions in cancer therapy, particularly its impact on the nutritional status of patients undergoing surgery for colorectal cancer. These studies are crucial for understanding how nutritional support can enhance recovery and treatment outcomes in cancer patients (Ural et al., 2024).

アナリシスノート

このような2次標準は、入手可能な場合にはUSP、EP、BPの1次標準にマルチトレーサビリティを提供します。

その他情報

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

脚注

To see an example of a Certificate of Analysis for this material enter LRAC2891 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.

おすすめ製品

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable